person
as of 2026-07-01David McDonnell, MD
at a glance
Roles: Study Director, Author, Investigator+Author
KOL signal score 8
1 publications · 1 high-value
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Alkermes, Inc.
Roles
Study Director, Author, Investigator+Author
KOL signal
8
Publications
1 (1 high-value)
Trial investigator
yes
Trials led
5
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
NCT02634346Phase 3Completed
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
NCT02161718Phase 2Completed
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
NCT04987229Phase 3Enrolling By Invitation
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064Phase 3Recruiting
A Phase 1 Safety Study in Adults With Schizophrenia
NCT02804568Phase 1Completed
Publications & congress
1
The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia.
The Journal of clinical psychiatry · 2026 · high-value
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
STUDY_DIRECTOR
trial